KRAS and non-small cell lung carcinoma: Among all patients with stage IV or recurrent, metastatic KRAS G12C mutant NSCLC with first line systemic therapy recorded after KRAS G12C mutation identification (n = 201), the median first-line rwPFS on systemic therapy for stage IV disease was 9.3 months (95% CI, 7.3–11.8 months) and median OS was 16.8 months (95% CI, 12.7–22.3 months; Figure 1).